Herantis Pharma: Invitation to 1H 2022 Report on August 25, 2022

Herantis Pharma Plc, Press Release, August 4, 2022 at 09:00 EEST

Herantis Pharma Plc("Herantis") an innovative biotech company developing new disease modifying therapies for Parkinson's disease, announced today that it will release 1H 2022 Report on Thursday August 25, 2022, at 08:00 EEST/ 07:00 CEST.

Members of the Herantis’ Management team will hold a live webinar to provide more details on the 1H 2022 Report with a live Q&A session (in English) for investors, analysts, and media at 10:00 EEST / 9:00 CEST.

Please join the webinar a few minutes in advance.

Registration details:

Date: Thursday, August 25, 2022

Time: 10:00 EEST / 9:00 CEST

Link to Registration: Herantis’ 1H 2022 Report Webinar

After registering, you will receive a confirmation email containing information about joining the webinar.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic version of the active parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visithttps://www.herantis.com